Stock Market Reviews

Read and share opinions on AGIO (Agios Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
  Nov 3, 2025
• AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
  Oct 31, 2025
• Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
  Oct 30, 2025
• Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
  Oct 30, 2025
• Agios Pharmaceuticals: Q3 Earnings Snapshot
  Oct 30, 2025
• Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease
  Oct 18, 2025
• Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
  Oct 17, 2025
• Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
  Oct 17, 2025
• Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
  Oct 16, 2025
• Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
  Sep 15, 2025
• FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)
  Sep 8, 2025
• AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
  Sep 5, 2025
• Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
  Sep 4, 2025
• Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders
  Aug 29, 2025
• Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders
  Aug 8, 2025
• Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
  Aug 4, 2025
• Agios shares drop after report notes deaths of Pyrukynd patients
  Aug 4, 2025